2022
DOI: 10.1111/jdv.18429
|View full text |Cite
|
Sign up to set email alerts
|

European guideline (EuroGuiDerm) on atopic eczema – part II: non‐systemic treatments and treatment recommendations for special AE patient populations

Abstract: The evidence-and consensus-based guideline on atopic eczema was developed in accordance with the EuroGuiDerm Guideline and Consensus Statement Development Manual. Four consensus conferences were held between December 2020 and July 2021. Twenty-nine experts (including clinicians and patient representatives) from 12 European countries participated. This second part of the guideline includes recommendations and detailed information on basic therapy with emollients and moisturizers, topical anti-inflammatory treat… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
152
0
18

Year Published

2022
2022
2024
2024

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 141 publications
(171 citation statements)
references
References 182 publications
1
152
0
18
Order By: Relevance
“…The European Task Force on Atopic Dermatitis (ETFAD) of the European Academy of Dermatology and Venerology (EADV) 2020 position paper reinforced the same concepts of patient selection and underlined the fact that AIT may be used in AD when approved indications for this treatment exist in the same patient, as in the case of concomitant respiratory allergic diseases ( 26 ). Finally, the most recent European Dermatology Forum in the European guidelines (EuroGuiDerm) 2022 on atopic eczema treatment recommended once more against the use of AIT as routine treatment, but suggested to consider it for selected patients with house dust mite, birch or grass pollen sensitization, and a history of clinical exacerbation after exposure to the causative allergen or a positive corresponding atopy patch test, as mentioned above ( 54 ).…”
Section: Discussionmentioning
confidence: 99%
“…The European Task Force on Atopic Dermatitis (ETFAD) of the European Academy of Dermatology and Venerology (EADV) 2020 position paper reinforced the same concepts of patient selection and underlined the fact that AIT may be used in AD when approved indications for this treatment exist in the same patient, as in the case of concomitant respiratory allergic diseases ( 26 ). Finally, the most recent European Dermatology Forum in the European guidelines (EuroGuiDerm) 2022 on atopic eczema treatment recommended once more against the use of AIT as routine treatment, but suggested to consider it for selected patients with house dust mite, birch or grass pollen sensitization, and a history of clinical exacerbation after exposure to the causative allergen or a positive corresponding atopy patch test, as mentioned above ( 54 ).…”
Section: Discussionmentioning
confidence: 99%
“…The management of AD focuses on three main targets: The avoidance of aggravating factors should improve the patient's quality of life. This requires a detailed diary of everyday activities and environments to reveal the factors that can be avoided or managed to significantly improve the patient's life with the disease [102].…”
Section: Treatment Of Atopic Dermatitismentioning
confidence: 99%
“…Se considera que GUIDAMEX debe actualizarse dentro de cinco años, pero según el desarrollo futuro del área podría llegar a verse esta necesidad antes. En la segunda mitad de 2022, justo antes de la publicación de GUIDAMEX, se actualizó la guía europea de la DA 22,23 . El contenido de esta guía será contemplado para la siguiente versión de GUIDAMEX.…”
Section: Detalles Administrativos De Guidamexunclassified